Introduction
The two defining features of hematopoietic stem cells (HSCs), self-renewal and multilineage differentiation, render these cells an attractive source for stem cell-based therapies. HSC transplantation can be a life-saving procedure in the treatment of a broad spectrum of disorders, including hematologic, immune, and genetic diseases. Bone marrow (BM) and mobilized peripheral blood stem cells are the most common HSC sources for transplantation; however, their use is restricted by the low availability of suitable human leukocyte antigen (HLA)-matched donors. An alternative approach, allowing the use of more rapidly available partly mismatched donors, involves the use of umbilical cord blood (UCB), which has been shown to be a rich source of HSCs. However, the stem cell number in a single UCB unit is not sufficient for transplantation into an adult. 1 These two issues, the lack of HLAmatched donors and the low number of stem cells available from common HSC sources for transplantation, especially in the case of UCB, present serious limitations to HSC transplantations. Clinical experience has shown that the stem cell dose (measured as CD34 + cell number) is related to patient survival and time required for engraftment, [1] [2] [3] indicating that amplification of hematopoietic stem and progenitor cells (HSPCs) is expected to be highly beneficial for their clinical application.
HSCs are a rare population of cells, representing less than 0.01% of all cells in the BM. During homeostasis, the stem cell pool is maintained at a relatively constant level. In contrast, several studies have shown that during hematopoietic stress, such as serial transplantations, HSCs can and will self-renew extensively. Studies by Pawliuk et al., Iscove, and Nawa have shown that following injection into lethally irradiated recipients, HSC numbers increased by 10-to 20-fold. 4, 5 When these cells were serially transplanted, the initial number of transplanted HSCs increased cumulatively by 8,400-fold after four successive passages. 5 Furthermore, it has been shown that a single purified HSC can reconstitute long-term hematopoiesis of lethally irradiated recipients, indicating robust in vivo doi: 10.1111/j.1749-6632.2012.06549.x self-replication capacity. 6 These studies have unequivocally demonstrated that HSCs can massively expand, and suggest that in vivo stem cells are exposed to specific factors/signals that promote their self-renewal and amplification.
Although HSC self-renewal divisions in vivo clearly occur, induction of self-renewal in vitro has been difficult. Even after several decades of research, the quest for factors that stimulate self-renewal in vitro is still continuing. The aim of these studies is to define the culture conditions that will support unlimited ex vivo expansion of HSCs from any source. To achieve this goal, stimulation of symmetrical selfrenewal divisions over unlimited differentiation divisions is required (Fig. 1) . Although many efforts have been made to expand stem cells, extensive in vitro amplification of HSCs without loss of their repopulating potential has not yet been achieved. Nonetheless, several cell-intrinsic and cell-extrinsic factors have been identified and shown to have potential to expand HSCs in culture. Here, we summarize how ex vivo HSC expansion protocols have evolved, briefly reviewing the early expansion attempts and then focusing on recent expansion approaches involving small molecules.
Regulation of HSC self-renewal by intrinsic factors
One of the remaining fundamental questions of stem cell biology is how self-renewal is regulated. Answers to this question would also substantially contribute to the success of ex vivo HSC expansion protocols. Valuable knowledge about factors influencing self-renewal has been gained from gene manipulation studies, which have identified multiple proteins that play an important role in the regulation of HSC self-renewal, including transcription factors, epigenetic modifiers, and cell cycle regulators ( Fig. 2) (reviewed in Refs. 7 and 8). Here, we will only highlight a few examples, representing different classes of proteins, such as DNA-binding, chromatin-binding, and RNA-binding factors.
One of the first genes described to play a role in HSC fate determination was HoxB4. Ectopic expression of this transcription factor resulted in robust (40-fold) expansion of transplantable murine HSCs, but did not coincide with the development of leukemia.
9,10 HSC amplification could also be stimulated by an extrinsically delivered TAT-HoxB4 fusion protein, although the HSC expansion levels achieved with this fusion protein were much lower compared with ectopic protein expression. 11 Additionally, other members of HoxA and HoxB clusters (e.g., HoxA4, HoxA9, HoxB6) have also been shown to regulate fate determination of adult HSCs. [12] [13] [14] [15] Overexpression of chromatin remodelers, such as members of the Polycomb group family of proteins (PcG), especially Ezh2 or Bmi1, have been shown to modulate HSC activity by preventing stem cell exhaustion or augmenting self-renewal, respectively. [16] [17] [18] The recent discovery of noncoding RNAs, including microRNAs, added an additional level of regulation to the network controlling HSC fate determination. 19, 20 Several microRNAs have been reported to modulate HSC fates, including the miR-125 family and miR-29a. [21] [22] [23] [24] [25] Genetic studies aimed to decipher the mechanism of self-renewal have indicated that self-renewal is regulated at various levels and by a complex network of interacting stimuli.
Although the highest expansion levels of HSCs have been reported after ectopic expression of cellintrinsic genes, introduction of genetic material is undesired in clinical protocols since continuous activation of self-renewal may lead to potential malignant transformation or to stem cell exhaustion. Therefore, mild and/or transient activation of self-renewal by extrinsic factors or molecules that perturb the activity of intrinsic HSC self-renewal regulators (described above) might be a preferred tool for ex vivo stem cell expansion.
Extrinsic regulators of HSC fates
The first attempts to ex vivo amplify HSCs with extrinsic factors focused on the use of hematopoietic cytokines, many of which are produced by the in vivo HSC microenvironment. Although the role of cytokines in blood lineage development has been indisputably established, their regulatory role on HSC self-renewal has been questioned. [26] [27] [28] Multiple cytokines, including SCF, Tpo, Flt-3L, IL-11, IL-3, IL-6, and GM-CSF, and combinations of these, have been studied in in vitro HSC expansion protocols of mouse and human cells. For details of the effects of distinct cytokines on HSC characteristics in culture, we refer to the excellent review by Sauvageau et al. 28 Knowledge gained from cytokine studies indicates that whereas in vitro cell survival and proliferation can be efficiently stimulated by several cytokines (especially SCF and Tpo), these cytokines by themselves are usually not sufficient to support self-renewal and they typically induce HSC differentiation, resulting at best in maintenance or modest stem cell amplification, but usually leading to progressive depletion of long-term repopulating cells. 29, 30 Single-cell cytokine cultures demonstrated that in vivo repopulating ability of mouse and human HSCs is gradually but inevitably lost, starting from the first in vitro cell division. [31] [32] [33] Nonetheless, the cocktail of SCF and Flt3L with IL-11 (mouse) or Tpo (mouse and human) was defined as the cytokine combination supporting the best HSPC survival, proliferation, and maintenance during in vitro culture, and is often used as the core cytokine mix to which other cytokines or expansion factors can be added (Table 1) . [55] [56] [57] To conclude, efforts to improve the rate of HSPC engraftment by ex vivo cytokine-based expansion protocols has been largely unsuccessful, indicating the need of additional factors/molecules in order to support HSC self-renewal and amplification in vitro.
Developmental regulators and HSC expansion
Recently, factors that do not necessarily qualify as typical hematopoietic growth factors but rather play an instructive role during ontogeny (i.e., at a time when the hematopoietic system is first developed and is rapidly expanding) have been shown to also regulate the adult stem cell compartment. These factors stimulate several developmentally conserved pathways, such as wingless-type (Wnt), Notch, Sonic hedgehog (Shh), and fibroblast growth factor (FGF) signaling. Adult HSCs have been shown to express receptors that can activate all of the aforementioned pathways, indicating that these pathways may be employed to extrinsically control HSC fate in culture.
Wnt proteins
The Wnt signaling pathway, known by its role in embryogenesis and cancer, regulates cell-to-cell interactions in a wide variety of tissues. A role for Wnt has been convincingly demonstrated in homeostasis of the intestinal stem cell compartment, 58 and a role for Wnt has been explored in HSC fate regulation. 59 Wnts are secreted glycoproteins, expressed by the fetal and adult HSC microenvironment. Addition of soluble Wnt proteins, such as Wnt3a or Wnt5a, to liquid cultures or cocultures with Wnttransduced stroma, enhanced mouse and human HSC survival, proliferation, and self-renewal, as measured by engraftment rate after transplantation into lethally irradiated recipients. [60] [61] [62] [63] Interestingly, it has recently been demonstrated that the level of Wnt signaling is critically important in regulating HSC self-renewal. 64 Binding of Wnt ligands to its receptor Frizzled triggers activation of the canonical signal transducer ␤-catenin and its FGFs, fibroblast growth factors; IGF-2, insulin growth factors 2; Angplts, angiopoietin-like proteins; ATRA, all-trans retonic acid; TEPA, tetra-ethylenepentamine; VPA, valproic acid; TSA, trichostatin A; 5aza, 5-aza-2 -deoxycytidine; BIO, 6-bromoindirubin-3 -oxime; SR1, StemRegenin1; PGE 2 , prostaglandin E 2 ; M, mouse; H, human; BM, bone marrow; SP, side population; UCB, umbilical cord blood; MPB, mobilized peripheral blood; SCF, stem cell factor; Tpo, thromopoietin; Flt3L, Ftl3 ligand; IL, interleukin; MGDF, megakaryocyte growth and development factor; w, week; d, day; CAFC, cobblestone area forming cell; CFU(-S), colony forming cell (spleen); CRU, competitive repopulating unit; SRC, NOD/SCID-repopulating cell; H4-AC, histone 4 acetylation.
translocation to the nucleus, leading to activation of Wnt target gene transcription. 65 Ectopic expression of a constitutively active form of ␤-catenin resulted in expansion of the stem cell pool. 59 In this study, upon activation of Wnt signaling, upregulation of HoxB4 and Notch1 were reported, suggesting a link between Wnt and Notch signaling pathways. Work of Duncan et al. supports cooperation of these two pathways in maintaining the HSC pool, thus demonstrating the importance of the Wnt pathway in cell proliferation and survival and a requirement of Notch for maintaining HSCs in an undifferentiated state. 66 
Notch pathway
Notch and Notch-ligands, such as Jagged-1, Jagged-2, and Delta-1, are expressed by HSCs and their microenvironment, indicating a potential role for Notch interactions in hematopoiesis. 67 Studies on the involvement of the Notch pathway in HSC fate regulation demonstrated that an immobilized form of Delta-1, but not its soluble form, can expand murine and human HSPCs in culture. Incubation of human UCB CD34 + cells with Delta-1 and cytokines resulted in increased numbers of NOD/SCID repopulating cells with secondary transplantation ability. Similar to the dependence of HSCs on Wnt-protein levels, the Notch-mediated effects were suggested to be dose-dependent, since HSPC expansion was observed only with lower Delta-1 concentrations. 68, 69 A subsequent clinical phase I trial showed rapid neutrophil recovery, enhanced myeloid engraftment, and no signs of graft-versus-host disease (GVHD) following transplantation with Delta-1-expanded human UCB cells, 70 although it remains unclear whether the UCB cells benefitted from the expansion protocol.
Shh/BMP signals
Cytokine-based expansion cultures of HSCs can also be improved by addition of other developmental factors, namely by soluble Sonic hedgehog proteins (Shh). Following Shh stimulation of human CD34 + CD38 -Lin -cells, enhanced cell proliferation and increased recovery of NOD/SCID repopulating cells were reported. 71 Additionally, Shh-induced HSPC expansion was suggested to be dependent on downstream bone morphogenic protein-4 (BMP-4) signaling, because inhibition of BMP-4 abrogated Shh-induced expansion. 71 Since human HSCs express BMP receptors, addition of soluble BMP-4 could also improve human HSPC proliferation and maintenance following in vitro culture. 72 
FGF signaling
The observation that murine HSCs express high levels of FGF receptors has led to investigation of the role of FGF signaling in HSPC fate regulation. Among this large protein family, FGF-1 and FGF-2 in particular were shown to maintain/expand multilineage, serially-transplantable, long-term repopulating HSCs when added to cytokine-and serumfree cultures of unfractionated mouse BM. 34, 35 However, addition of classical cytokines to these cultures and stimulation of proliferation overruled FGF-dependent stem cell preservation. Moreover, FGFs could not support the maintenance of an undifferentiated state of purified murine HSCs in culture, and only appeared active when stromal elements were present, suggesting an indirect nature of the FGF effects. 35 
IGF and Angptls
Recently, several soluble proteins produced by the endothelium and fetal liver, including insulin-like growth factor 2 (IGF-2), IGF binding protein 2 (IGFBP-2), and angiopoietin-like proteins (Angptls), have been identified as growth factors that can enhance ex vivo expansion of HSCs. Zhang et al. reported that addition of IGF-2, a protein expressed in fetal liver cells, to serum-free cultures of fetal liver HSCs resulted in increased stem cell frequency in a transplantation setting. 36 Shortly afterward, it was reported that IGFBP-2 displayed similar or even better stem cell-supporting effects and that IGF-2 could be replaced by IGFBP-2 in ex vivo HSC expansion cultures. 73 These cultures also contained a combination of a developmental factor, FGF-1 (mentioned above), and two cytokines, SCF and Tpo. The efficiency of this expansion cocktail could be further enhanced by addition of angiopoietin-like proteins, which 37 include several members, such as Angplt2, Angplt3, Angplt5, and Angplt7. Culture of murine HSCs with these factors resulted in a 30-fold net expansion of long-term repopulating HSCs, one of the highest HSC amplifications achieved to date by extrinsic factors. Similar expansion levels have also been reported in human HSC cultures supplemented with the Lodish and Zhang cocktail. 37, 73, 74 Pleiotrophin Another novel microenvironmental factor, pleiotrophin, expressed by human brain endothelial cells, has recently been reported to be essential for HSC maintenance. Mouse HSCs cultured in the presence of pleiotrophin displayed a net increase in in vivo-measured stem cell frequency and enhanced secondary repopulation activity upon serial transplantation. Pleiotrophin was also shown to improve ex vivo expansion of human CD34 + CD38 -Lin -HSCs, albeit to a lesser extent compared with murine cells. Pleiotrophin-mediated expansion was abrogated by addition of specific PI3K or Notch inhibitors to the culture medium, suggesting involvement of these pathways in the pleiotrophin stem cell-enhancing effects. 38 Additionally, whereas pleiotrophin deficiency did not show any in vivo steady-state hematopoietic effects, repression of pleiotrophin in stromal cells resulted in defective hematopoiesis. 75 The studies discussed above indicate the potential usefulness of exploiting the molecular pathways involved in stem cell self-renewal in improving ex vivo HSPC amplification cultures. The challenge remains to integrate the various cell-intrinsic and cellextrinsic signals into the regulatory networks controlling HSC fate outcomes and to decipher how these factors are linked with each other. Likely, the balance of various coregulated stimuli, acting simultaneously or sequentially, is crucial for HSC fate outcomes, and the ability to mimic the orchestra of these signals may lie in the success of in vitro stem cell-expansion protocols.
Small molecules
In recent years, evidence has accumulated suggesting that in addition to natural cytokines/factors chemical compounds can also have potent effects on stem cell expansion protocols (Table 1) . Studies were launched to assess the ability of such compounds to control stem cell fates in culture, where the effects ranged from enhancement of stem cell expansion to stimulation of lineage-specific differentiation, including effects on iPS reprogramming efficiency.
76-78
ATRA Retinoic acid (RA), a derivative of vitamin A (retinol) normally present in low physiological concentration in serum, represents a naturally occurring small molecule. 79 Retinoids have been shown to play important roles in development, differentiation, and homeostasis of a wide variety of cell types. The retinoic acid receptor agonist all-trans retinoic acid (ATRA) has a well-documented effect on hematopoietic cells in cancer treatment, where it can induce differentiation of leukemic cells. 80 Studies with RA receptor (RAR) deletion have revealed the importance of retinoids in normal hematopoiesis, since RAR-␥ knock-out mice showed markedly reduced HSC numbers. 81 However, the utility of retinoids for ex vivo HSPC expansion is unclear. Purton et al. suggested that addition of ATRA to cultures of mouse HSPCs enhanced the maintenance of short-and long-term repopulating cells and augmented self-renewal in serial transplantation experiments. 39, 40 Additionally, increased Notch1 and HoxB4 mRNA levels were observed upon ATRA stimulation, suggesting that ATRA effects could be at least partially mediated via known cell-intrinsic regulators of HSC self-renewal. 81 On the other hand, retinoic acid was also reported to negatively affect HSPC ex vivo expansion, since inhibition of retinoid signaling resulted in enhanced HSPC self-renewal in vitro. 82 Therefore, the effects of retinoids on in vitro HSPC self-renewal and differentiation need further investigation.
Copper chelator, TEPA It has been shown that increased cellular copper levels can improve ATRA-stimulated differentiation of leukemic cells. 83 Additionally, ions such as magnesium, calcium, or copper (Cu) are known to play an important role in cell function, since disturbed homeostasis of these ions is associated with clinical symptoms. Copper malnutrition resulted in hematopoietic cell maturation arrest but did not affect progenitor cell development, which suggests that cellular Cu balance may play a role in HSPC proliferation and differentiation. Studies on modulation of cellular Cu content during ex vivo culture demonstrated that elevated copper levels accelerated cell maturation, whereas decreased Cu levels, achieved by addition of the Cu chelator tetraethylenepentamine (TEPA), attenuated ex vivo human HSPC differentiation, resulting in expansion of early progenitor cells. TEPA-supplemented, longterm cytokine cultures of CD34 + cord blood cells significantly increased the number of CD34 + CD38 -cells and enhanced NOD/SCID repopulating capacity. 41, 42 A phase I/II clinical trial in which TEPA-cultured cord blood cells were coinfused with uncultured cord blood cells showed the safety of this approach. 43, 84 Although engraftment of TEPAtreated cells could be observed in almost all study subjects, the time required for neutrophil and platelet recovery was not changed compared with uncultured cord blood cells. 84 The efficiency of TEPA-cultured HSPC transplantation product is currently under investigation in an ongoing phase II/III study.
HDIs
Since stem cells are believed to be characterized by a specific (transcriptionally permissive) epigenetic status, epigenetically active compounds could possibly modulate stem cell fates. Several small molecules have been identified that alter the epigenetic status of cells. Histone deacetylase inhibitors (HDIs) or demethylating agents are an example of such compounds. Several groups have studied the effects of valproic acid (VPA), an epigenetic drug known for its anticancer activity, on regulation of in vitro HSC fate determination. Addition of VPA to cultures of murine or human HSPCs preserved the expression of primitive markers and an HSC phenotype. 44, 45, 85 VPA treatment was shown to maintain CFU-S activity in murine HSCs and resulted in elevated chimerism levels upon transplantation into lethally irradiated recipients. [44] [45] [46] Similar effects on the ex vivo expansion of human-mobilized peripheral blood CD34 + HSCs were observed upon treatment with another HDI, chlamydocin. 47 Additionally, a combination of two epigenetic drugs was shown to additively affect HSC maintenance and/or expansion in culture. 48, 86 Sequential addition of a demethylating agent, 5-aza-2 -deoxycytidine methyltransferase (5azaD), and the HDI trichostatin A (TSA) to various cytokine cocktails has been shown to improve maintenance of stem cells in culture, compared with single compound treatment. 48, 86 As expected, in these HSCs, HDI exposure increased histone acetylation, whereas 5aza decreased methylation. 48 HDI treatment has also been shown to result in upregulation of cell-intrinsic HSPC fate regulators such as HoxB4 and AC133, in activation of Wnt signaling, and in downregulation of p21. Nevertheless, the exact mechanism of HDI-stimulated HSC expansion remains unclear. [44] [45] [46] [47] [48] BIO Small molecules that specifically target signaling pathways that play an important role in HSC selfrenewal and maintenance could be beneficial for ex vivo expansion protocols. The synthetic compound 6-bromoindirubin-3 -oxime (BIO) can modulate Wnt signaling activity by targeting GSK3␣ and ␤, a negative regulator of Wnt signals. 50 Stimulation of cord blood CD34 + cells with BIO led to accumulation of slowly dividing cells and enhanced replating activity. 50 Additionally, the exposure of cultured CD34 + cells to BIO significantly increased engraftment and chimerism levels of the NOD/SCID repopulating cells. 49 As a GSK3␤ inhibitor, BIO treatment resulted in accumulation of ␤-catenin and its nuclear localization; however, the expression of Wnt target genes was not changed upon treatment. 49, 50 Therefore, the key mechanism of BIO, and how it is responsible for enhanced HSPC activity, remain unknown.
SR1
Recent reports have shown that unbiased screens to search for factors that are able to maintain/expand HSCs can identify novel compounds with HSC self-renewal stimulatory activity. Using high-throughput screening, Boitano et al. identified an acryl hydrocarbon receptor (AhR) antagonist, referred to as StemRegenin1 (SR1), that was capable of enhancing human CD34 + HSC cell amplification. 51 Cord blood CD34 + cells cultured in the presence of SR1 led to a high net increase in the number of CD34 + cells. Importantly, SR1-treated human cells demonstrated a 17-fold increase in cell numbers that were capable of hematopoietic reconstitution of sublethally irradiated mice and showed enhanced multilineage, long-term potential. Although it has been shown that hHSCs express AhR, which has been implicated in pathways regulating hematopoiesis, pathways including HES-1, ␤-catenin, and CXCR4, the exact mechanism of SR1-induced HSC expansion is not known yet. 51 
PGE 2
Another novel compound, the small lipid mediator prostaglandin E 2 (PGE 2 ), was identified as a regulator of HSC self-renewal using high-throughput library screens in zebrafish. 52 Chemicals enhancing PGE 2 synthesis have been shown to increase HSC numbers in zebrafish and mouse embryos, whereas those blocking its synthesis decrease stem cell numbers, indicating that modulation of the prostaglandin pathway might affect stem cell characteristics. 52 Components of the prostaglandin pathway and PGE 2 receptors are present on both mouse and human stromal cells and HSCs. 52, 53 The enhancing role of PGE 2 on adult HSCs has been demonstrated in competitive transplantation models, where short stimulation of mouse cells with PGE 2 prior to transplantation increased the frequency of short-and long-term repopulating cells. 52 Hoggatt et al. confirmed the stimulatory effects of PGE 2 on mouse HSCs and additionally reported that the induced competitive advantage of treated HSCs remained upon serial transplantation. Although the exact mechanism of PGE 2 is not known, studies have shown that the PGE 2 effects might be explained by stimulation of HSC survival, proliferation, and self-renewal associated with upregulation of survivin, an inhibitor of apoptosis, and with a reduction of the active intercellular form of caspase-3. Furthermore, PGE 2 may enhance HSPC homing, as suggested by upregulated expression of the CXCR4 gene. 53 
NR-101
The studies reported above have employed the use of chemical compounds added to cultures that also contain cytokines. Yet, small molecules have also been used as a full replacement of cytokines. Tpo is one of the most efficient cytokines supporting HSC proliferation and survival in culture and is widely used in HSC expansion protocols. Several small molecules have been chemically synthesized that are able to activate c-MPL, the receptor for Tpo. Nishino et al. screened more than 400 of these molecules for their HSC stimulatory role and found a novel small molecule c-MPL agonist, NR-101, that more effectively expanded HSCs ex vivo compared with Tpo. Following culture, NR-101 increased CD34 + and CD34 + CD38 -cell numbers and NOD/SCIDrepopulating cell frequencies compared with Tpo or with fresh cord blood CD34 + cells. NR-101 was shown to activate the major pathways of Tpo/c-MPL signaling, but displayed extended signal activation compared to Tpo. 54 Finding that HSPC fate can be modulated chemically by addition of small molecules to the culture media is convenient in light of ex vivo HSC expansion and offers, next to cytokines and developmental factors, an additional level of control of HSC selfrenewal and differentiation in vitro. The promising potential of chemically enhanced HSC self-renewal and its cooperation with other self-renewal factors should be carefully evaluated and tested for use in clinical stem cell expansion protocols.
Conclusions
Although HSCs can expand extensively in vivo, conditions that reliably induce robust HSC expansion in vitro have yet to be discovered. Expansion attempts with the use of hematopoietic cytokines were rather disappointing and therefore diminished the initial enthusiasm of ex vivo stem cell expansion. A potential role of developmental factors and the discovery that self-renewal can be controlled by chemical compounds has revived this hope. Today, thousands of molecules are screened for their effects on HSC fates, and the utility of these factors for in vitro stem cell expansion is being investigated. Experience gained from many years of research indicates that the most comprehensive approach to develop optimal HSC expansion conditions may involve a combination of methods. It is likely that these conditions would involve multiple biological and chemical compounds that act in concert to induce cell survival and division while simultaneously preventing stem cell differentiation. Accordingly, several signaling pathways and/or compounds have been reported to act additively or synergistically to modulate HSPC fates in culture. 85, 87, 88 Additionally, methods that improve HSC homing and survival after transplantation could also be combined with ex vivo HSC expansion to potentially further enhance the efficiency of HSPC engraftment. Difficulties in defining HSC expansion conditions result partly from insufficient understanding of the molecular mechanisms controlling HSC fate determination. Identification of key molecules and the interaction networks important for self-renewal could significantly improve expansion attempts and may also lead to development of specific compounds targeting these self-renewal factors. Importantly, the challenge remains to assess to what extent it will be possible to generate fully functional HSCs, and their derivatives, for future clinical regenerative medicine applications.
